**C. Appendix 3. Detailed results of positive signals (FDR < 0.05; Specificity** ≥ **0.99) of other mental and central disorders not stated in SPCs related to statins reported as ADR in Vigiaccess™ database and analyzed by a contrasted approach of Bayesian confidence propagation neural network (BCPNN) extended to the multiple comparison setting for active ingredients groups**

Interpretation of items: drug code: active ingredient reported; event effect: ADR reported; count: number of couples 'active ingredient-ADR' reported; expected count: couples 'active ingredient-ADR' expected; post.H0: posterior probability of null hypothesis; n11/E: ratio between the count observed and the count expected of the corresponding couple; drug margin: number of reports of a drug; event margin: number of reports of an event; FDR: false discovery rate; FNR: false negative rate; Se: Sensitivity (\* ≥ 0.20); Sp: Specificity.


*Loss of special senses not reported in SPCs: blindness, unilateral blindness, deafness, unilateral deafness, anosmia, ageusia, balance disorder.*


*Early Signal Detection: Data Mining of Mental Disorders with Statins DOI: http://dx.doi.org/10.5772/intechopen.105504*

*Other mental health problems not stated in SPCs: anxiety, bipolar disorder, psychiatric symptom, psychotic disorder, emotional disorder, emotional distress.*


*Suicide not stated in SPCs: complete suicide, suicide attempt, suicidal ideation, suicidal behavior.*


